J. Ajani, T. D’amico, K. Almhanna, D. Bentrem, J. Chao, P. Das, C. Denlinger, P. Fanta, F. Farjah, C. Fuchs, H. Gerdes, M. Gibson, R. Glasgow, J. Hayman, S. Hochwald, W. Hofstetter, D. Ilson, D. Jaroszewski, K. Johung, R. Keswani, L. Kleinberg, W. Korn, S. Leong, Catherine Linn, A. Lockhart, Quan P. Ly, M. Mulcahy, M. Orringer, K. Perry, G. Poultsides, W. Scott, V. Strong, M. Washington, B. Weksler, C. Willett, C. Wright, Debra Zelman, Nicole R Mcmillian, Hema M. Sundar
2016.10.1Journal of the National Comprehensive Cancer Network
tlooto Summary
The recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease are discussed.
Abstract
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Several advances have been made in the staging procedures, imaging techniques, and treatment approaches. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer provide an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. This manuscript discusses the recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease.
Citation format
AJANI, J., et al. Gastric cancer, version 3.2016; clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2016, 14: 1286–1312.